Chelsea M. Morken, PharmD (@ChelseaMorken) explains the pathophysiology of rheumatoid arthritis (RA), describes the literature regarding cardiovascular risks with Janus-kinase inhibitors and recognizes appropriate initial therapy based on patient specific factors.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
